Posology: Adult Males (including older people): One 10.8 mg depot of Zoladex LA injected subcutaneously into the anterior abdominal wall, every 12 weeks.
Adult Females: One 10.8 mg depot of Zoladex LA injected subcutaneously into the anterior abdominal wall, every 12 weeks.
Renal impairment: No dosage adjustment is necessary for patients with renal impairment.
Hepatic impairment: No dosage adjustment is necessary for patients with hepatic impairment.
Paediatric population: Zoladex LA is not indicated for use in children.
Method of administration: For correct administration of Zoladex, see instructions on Patient Counselling Information.
The instruction under Patient Counselling Information has to be read prior to administration.
Caution is needed when administering Zoladex LA into anterior abdominal wall due to the proximity of underlying inferior epigastric artery and its branches.
Extra care to be given to patients with a low BMI or who are receiving anticoagulation medication (see Precautions).
Care should be taken to ensure injection is given subcutaneously, using the technique described in Patient Counselling Information Do not penetrate into a blood vessel, muscle or peritoneum.
In the event of the need to surgically remove a Zoladex LA implant, it may be localised by ultrasound.
For special precautions for disposal and other handling see Special precautions for disposal and other handling under Cautions for Usage.
Children: Zoladex LA 10.8 mg is not indicated for use in children.